ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

リバスチグミン

Rivastigmine

HCID 77991
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
123441-03-2
標準SMILES
CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1
InChIKey
XSVMFMHYUFZWBK-NSHDSACASA-N
分子式
C14H22N2O2
平均分子量
250.34 g/mol
単同位体質量
250.16812795

概要

Rivastigmine is a carbamate ester obtained by formal condensation of the carboxy group of ethyl(methyl)carbamic acid with the phenolic OH group of 3-[(1S)-1-(dimethylamino)ethyl]phenol. A reversible cholinesterase inhibitor. It has a role as an EC 3.1.1.8 (cholinesterase) inhibitor, a cholinergic drug and a neuroprotective agent. It is a carbamate ester and a tertiary amino compound. It is a conjugate base of a rivastigmine(1+).

名称と識別子

優先名称
Rivastigmine
IUPAC
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
現地名
リバスチグミン
英語名
Rivastigmine
分子式
C14H22N2O2
分子量
250.34

名称と別名

rivastigmine123441-03-2PrometaxENA 713 free baseNimvastidRivastigmine Tevarivastigmine hexalRivastigminaRivastigmine sandozSDZ-ENA-713Rivastigmine Transdermal SystemSDZ-212-713
名称をさらに表示
リバスチグミンリバスチグミン (JAN)N-エチル-N-メチルカルバミド酸3-[(1S)-1-(ジメチルアミノ)エチル]フェニル3-[(1S)-1-(ジメチルアミノ)エチル]フェニル N-エチル-N-メチルカルバマートメチルエチルカルバミド酸3-[(S)-1-(ジメチルアミノ)エチル]フェニル(S)-リバスチグミンリバスティグミンN-エチル-N-メチルカルバミド酸3-[(S)-1-(ジメチルアミノ)エチル]フェニルイクセロンリバスタッチエチルメチルカルバミド酸3-[(S)-1-(ジメチルアミノ)エチル]フェニルRIVASTIGMINE HYDROGEN TARTRATEmineEXELONRivastigmine baseRivastigKabaratincabalatineRevastigmineRivastigiMine
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamatem-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamateONO-2540PKI06M3IW0SDZ 212-713ENA-713D3-[(1S)-1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamateSDZ-212713

物性

構造計算による物性

XLogP
2.3
極性表面積
32.8 Ų
水素結合供与体数
0
水素結合受容体数
3
回転可能結合数
5
重原子数
18
形式電荷
0
複雑度
269

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Acetylcholinesterase inhibitor

LogP2.3
Solubility2.04e+00 g/L
Human Drugs · 6 件

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

Physical DescriptionSolid
Dissociation Constants · 2 件

8.8

8.99

Collision Cross Section165 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

物理化学的性質

比旋光度
20 · D20 -32.1° (c = 5 in ethanol)
沸点
316.2 · 316.2±34.0 °C(Predicted)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 5 件

This chemical does not meet GHS hazard criteria for 6.2% (1 of 16) of reports.

Danger

H300 (31.2%): Fatal if swallowed [Danger Acute toxicity, oral]

P261, P264, P270, P271, P273, P280, P301+P316, P302+P352, P304+P340, P317, P321, P330, P362+P364, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 16 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 2 (31.2%)

毒性情報

Hepatotoxicity · 1 件

In large placebo controlled trials, rivastigmine therapy was not associated with an increased rate of serum enzyme elevations compared to placebo treatment and no instances of clinically apparent liver injury with jaundice were reported. Nevertheless, since its introduction into clinical use, rivastigmine (administered by transdermal patch) has been implicated in at least one report of clinically apparent hepatotoxicity with mild jaundice. The time to onset was 2 months and the serum enzyme elevations had a mildly hepatocellular pattern. Mild rash and eosinophilia were also present, but autoimmune features were not. Recovery was complete within 5 weeks of drug discontinuation.

Adverse Effects · 1 件

Adverse effects of rivastigmine have received thorough study as it has been on the market for some time. The main adverse effects associated with the use of rivastigmine are gastrointestinal. The primary symptoms are nausea and vomiting. These acute effects primarily occur during the initial dose-escalation phase of therapy with upward dose titration of the drug to achieve a therapeutic dose. These events can be minimized using a slow titration schedule and taking the medication with food if prescribing an oral formulation. In a study done to analyze the safety and tolerability of cholinesterase inhibitors used to treat Alzheimer dementia, researchers found rivastigmine to be the drug to have the highest rate of gastrointestinal side effects.

化学と産業

薬理情報

ATC Code · 3 件

N06DA03

N - Nervous system

QN - Nervous system

Protein Binding40%
Pharmacodynamics · 1 件

Rivastigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. While the precise mechanism of rivastigmine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact.

Mechanism of Action · 1 件

Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.

Biological Half-Life1.5 hours
Metabolism/MetabolitesRivastigmine is rapidly metabolized by cholinesterase-mediated hydrolysis.
FDA Pharmacological Classification · 6 件

PKI06M3IW0

RIVASTIGMINE

関連反応

3 件
反応記録を作成
HRID 532100 の反応式
HRID 532100生成物として
HRID 907502 の反応式
HRID 907502反応物として
HRID 1425636 の反応式
HRID 1425636生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
123441-03-2
PubChem CID
77991
DTXSID
DTXSID7023564
ChEMBL
CHEMBL636
ChEBI
CHEBI:8874
UNII
PKI06M3IW0
EC Number
602-936-0
Nikkaji
J982.502I
比重(密度)
1.038 · 1.038±0.06 g/cm3(Predicted)
闪点
145 ℃ · 145℃
貯蔵温度
-20 °C · Sealed in dry,Store in freezer, under -20°C
溶解性
Chloroform (Sparingly), Ethyl Acetate (Slightly)
外見
Powder
酸解離定数(Pka)
8.99 · pKa 8.99 (Uncertain)
色
Colorless to light yellow
主な用途
医薬品(低分子化合物)
InChI
InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1
InChIKey
XSVMFMHYUFZWBK-NSHDSACASA-N
SMILES
C(OC1=CC=CC([C@@H](N(C)C)C)=C1)(=O)N(CC)C
CAS データベース
123441 · 123441-03-2(CAS DataBase Reference)
Toxicity Summary · 1 件

Toxicity to the drug, while rare, should be carefully monitored. Common toxicity manifestations include severe gastrointestinal reactions, allergic cutaneous reactions, and central nervous system effects. All cutaneous reactions due to usage of the patch should prompt immediate removal of the patch for at least 48 hours before reapplying in a new area. Therapy should be discontinued if symptoms last longer than 48 hours or a severe cutaneous reaction occurs.

Drug Induced Liver Injury · 5 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

rivastigmine

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

安全データ

wgk
WGK 3
ridadr
UN 2810 6.1 / PGIII
hs_code
2924296000
Hazard Classifications
Acute Tox. 2 OralAquatic Chronic 2
ストレージクラス
6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials

Established Pharmacologic Class [EPC] - Cholinesterase Inhibitor

Mechanisms of Action [MoA] - Cholinesterase Inhibitors

Rivastigmine is a Cholinesterase Inhibitor. The mechanism of action of rivastigmine is as a Cholinesterase Inhibitor.

RIVASTIGMINE

MeSH Pharmacological Classification · 2 件

Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.

Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.

Absorption, Distribution and Excretion · 3 件

Rivastigmine is extensively metabolized primarily via cholinesterase-mediated hydrolysis to the decarbamylated metabolite NAP226-90. Renal excretion of the metabolites is the major route of elimination. Less than 1% of the administered dose is excreted in the feces.

1.8 to 2.7 L/kg

renal cl=2.1-2.8 L/hr

Cellular LocationsCytoplasm

用途と製造

UsesUse (kg; approx.) in Germany (2009): >100
応用分野 · 4 件

用途強力なコリンエステラーゼ及 びブチリルコリンエステラーゼの阻害剤で す。

来歴Rivastigmine was discovered by Marta Weinstock-Rosin of the Department of Pharmacology at the Hebrew University of Jerusalem and sold to Novartis by Yissum for commercial development. Rivastigmine, sold under the brand name Exelon among others, is an acetylcholinesterase inhibitor used for the treatment of dementia associated with Alzheimer's disease and with Parkinson's disease.

使用Antidepressant

一般的な説明Rivastigmine (Exelon, EA 713) is apseudoirreversible noncompetitive carbamate inhibitor ofAChE. Although the half-life is approximately 2 hours,the inhibitory properties of this agent last for 10 hours becauseof the slow dissociation of the drug from the enzyme.The Food and Drug Administration (FDA) approved its usein mild-to-moderate Alzheimer disease in April 2000. InJuly 2007, rivastigmine was granted approval for use inmanaging mild-to-moderate dementia associated withParkinson disease.

上流・下流製品情報

上流原料

(S)-1-(3-(ethyl(methyl)carbamoyloxy)phenyl)-N,N-dimethyl-N-((S)-1-phenylethyl)ethanaminium iodideRivastigmine hydrochlorideCarbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-aminoethyl]phenyl ester1257519-35-9Methanamine, N-(benzoyloxy)-N-methyl-3-[1-(ジメチルアミノ)エチル]フェノール(S)-3-[1-(ジメチルアミノ)エチル]フェノールN-エチル-N-メチルカルバモイルクロリドRivastigmine EP Impurity Eエチル(メチル)カルバミン酸3-(1-ヒドロキシエチル)フェニル(R)-3-(1-hydroxyethyl)phenylethyl(methyl)carbamate

補足説明

定義ChEBI: A carbamate ester obtained by formal condensation of the carboxy group of ethyl(methyl)carbamic acid with the phenolic OH group of 3-[(1S)-1-(dimethylamino)ethyl]phenol. A reversible cholinesterase inhibitor.